Photo of Elisa Port

Elisa Port

  • ASSOCIATE PROFESSOR Surgery
Print ProfilePrint Profile

Certifications

  • American Board of Surgery

Clinical Focus

Education

  • MD, Mount Sinai School of Medicine

  • BA, Dartmouth College

  • Residency, General Surgery
    Cedars-Sinai Medical Center

  • Residency, General Surgery
    Long Island Jewish Medical Center

Biography

    I am a surgeon who specializes in the care and treatment of patients with breast cancer, and those at increased risk for breast cancer. I have extensive experience with sentinel lymph node biopsy, nipple sparing mastectomy, and the newest techniques in breast cancer surgery for both invasive breast cancer and DCIS.

    I am the author of a variety of publications on the role of sentinel lymph node biopsy in breast cancer, the role of MRI in patients at high risk for breast cancer, and I have received a Komen Foundation Grant investigating the role of PET scanning in breast cancer.  I recently completed an NCI funded clinical trial investigating the effects of the COX2 inhibitor, Celebrex, on breast cancer tissue.

    I am a member of many professional organizations including the Society of Surgical Oncology, the American Society of Breast Diseases, the American Society of Breast Surgeons, and the American College of Surgeons Oncology Group.


    In the News
    Dr. Port and Dr. Raptis discuss breast cancer in The Daily News feature The Daily Check Up.

    View the PDF

Awards

  • 2003 -
    Fellow
    American College of Surgeons

  • 1992 -
    Honors in Surgery
    Mount Sinai School of Medicine

  • 1986 -
    Third Honor Group
    Dartmouth College

Research

Biopsy Research

Applications of sentinel lymph node biopsy for breast cancer

Susan G. Komen Foundation Research Grant

Study of the role of Positron Emission Tomography (PET) scanning in the pre-operative management of patients with breast cancer

NCI Sponsored Trial

Investigating COX-2 inhibition and aromatase activity in breast cancer

MRI Study

MRI in women at increased risk for breast cancer

Publications

Port ER, Patil S, Stempel M, Morrow M, Cody HS. The Number of Nodes Removed in Sentinel Node-Negative Breast Cancer Patients is Significantly Related to Patient Age and Tumor Size: A New Source of Bias in Morbidity Assessment? . Cancer 2010 FEB;.

Chung A, Schoder H, Sampson M, Morrow M, Port ER. Incidental Breast Lesions Identified by 18F-Fluorodeoxyglucose-Positron Emission Tomography. . Ann Surg Oncol 2010 FEB;.

Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Flowers C, Troyan S, Garber J, Olopade O, Hylton N, Port ER, Campbell MC, Esserman LJ. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. . Breast Can Res Treat 2010; 119(1): 137-144.

Karam AK, Hsu M, Patil S, Stempel M, Traina TA, Ho AY, Cody HS, Port ER, Morrow M, Gemignani ML. Predictors of completion axillary lymph node dissection in patients with positive sentinel lymph nodes. . Ann Surg Oncol 2009 JUL; 16(7): 1952-1958.

Disa JJ, Port ER. More than 200,000 women will be diagnosed with breast cancer in 2008. . Cancer J. 2008; 14(4): 214-215.

Karam A, Stempel M, Cody III HS, Port ER. Reoperative sentinel lymph node biopsy after previous mastectomy.. J Am Coll Surg 2008 OCT; 207(4): 543-548.

Sacchini V, Beal K, Goldberg J, Montgomery L, Port ER, McCormick B. Study of quadrant high-dose intraoperative radiation therapy for early-stage breast cancer. . Br J Surg 2008 SEPT; 95(9): 1105-1110.

Flynn LW, Park J, Patil SM, Cody III HS, Port ER, . Sentinel lymph node biopsy is successful and accurate in male breast carcinoma. . J Am Coll Surg 2008 APR; 206(4): 616-621.

Chan SW, LaVigne K, Port ER, Fey Jane V, Brogi E, Cody HS. Does the benefit of sentinel node frozen section vary between patients with invasive duct, invasive lobular and favorable histologic subtypes of breast cancer? . Ann Surg 2008 JAN; 247(1): 143-149.

Port ER, Garcia-Etienne CA, Park J, Fey J, Borgen PL, Cody HS. Reoperative sentinel lymph node biopsy: a new frontier in the management of ipsilateral breast tumor recurrence. . Ann Surg Oncol. 2007 AUG; 14(8): 2209-2214.

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Port did not report having any of the following types of financial relationships with industry during 2013 and/or 2014: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central

Address

Faculty Practice Associates Floor 12th Floor
5 East 98th Street
New York, NY 10029

Tel: 212-241-3806

Address

Faculty Practice Associates Floor 12th floor Room 12-85
5 East 98th Street
New York, NY 10029


Address

Klingenstein Pavillion Floor 1st floor Room Dubin Breast Center
1176 Fifth Avenue
New York, NY 10029

Dubin Breast Center

Klingenstein Pavilion
1176 Fifth Avenue, 1st Floor
New York, NY 10029

Tel: 212-241-3806
Fax: 212-202-4590
Get Directions

Office Hours:
  • Monday 9:00am - 5:00pm
  • Wednesday 9:00am - 5:00pm
Insurance Plans
  • Aetna
  • Beech Street
  • Blue Cross/ Blue Shield
  • Cigna
  • GHI
  • HealthNet
  • HealthPlus, Inc.
  • Local 1199
  • Magnacare
  • Medicare
  • MultiPlan, Inc.
  • Oxford Health Plans
  • United Health Care Empire Plan
  • United Healthcare